The outbreak of COVID-19 has a great impact on every aspect of the medical device industry, which includes the cardiac implants devices market. The number of patient visits during the pandemic has drastically reduced despite having access to emergency in the cardiology department. Even the treatment proximity to infected patients with COVID 19 is a challenge for cardiologists. The access is restricted to essential care only and the temporary close of cardiology centers has drastically reduced cardiac surgeries as the total healthcare providers are engaged with COVID 19. Major players in the cardiac implants industry such as Medtronic Plc have reported a decline in revenue of 6 billion USD in Q4, 2020.
Diabetes, overweight and obesity, unhealthy diet, physical inactivity, excessive alcohol use are the main causes of heart diseases. The increase in the incidence of cardiovascular diseases and the geriatric population are the driving factors for the cardiac implants market. The World Health Organization stated that Cardiovascular diseases (CVDs) are the number one cause of death globally, which are a group of disorders of the heart and blood vessels that include coronary heart disease, rheumatic heart disease, cerebrovascular disease and other conditions. In December 2020, a study on ‘CV Disease Burden, Deaths Rising Around the World’ by American College of Cardiology reported that cardiovascular disease nearly doubled to 523 million in 2019 from 271 million in 1990. Cardiovascular disease deaths steadily increased to 18.6 million in 2019 from 12.1 million in 1990, with ischemic heart disease and stroke being the majority of cardiovascular disease deaths globally in 2019. They have also stated that the Global Burden of Diseases study continues to track and benchmark the progress of cardiovascular diseases and acts as a platform in the reduction/control of cardiovascular disease and risk factor burden.
Click Here to Download Sample Report >>https://www.sdki.us/sample-request-114548
Cardiac implants are considered to be a great asset for heart patients, which regularly helps to monitor patient’s heart beat and detect irregularities in the cardiac rhythms. Implantable Cardioverter-Defibrillator (ICD) is one such cardiac implant that supports the weak cardiac patients with the programs such as low-energy pacing, high energy shock. Increase in prevalence of cardiovascular diseases, advancements in surgical techniques, awareness on preventive care are propelling the market growth. Hence, owing to above mentioned factors, the market is expected to witness significant growth in the future.
Key Market Trends
Implantable Cardioverter-Defibrillators (ICDs) Segment is Expected to Grow Faster and Dominate the Market Over The Forecast Period
According to World Health Organization in 2020, it is estimated that 17.9 million people died from cardiovascular diseases each year which is 32% of all global deaths, out of which 85% were due to heart attack and stroke. They have also stated that by addressing behavioral risk factors such as tobacco use, physical inactivity, unhealthy diet and obesity, and harmful use of alcohol most cardiovascular diseases can be prevented, but it is important to detect cardiovascular diseases as early as possible to minimize their effect on individuals. Smoking is a major key factor that leads to heart diseases.
American Heart Association stated that in 2018, 53 895 deaths are caused due to arrhythmias as the primary cause. The prevalence of atrial fibrillation in the United States was estimated to be 12.1 million by 2030. Considering the fact that the increase in the prevalence of heart diseases and the increase in the geriatric population, the scope for heart procedures and especially cardiac implants is estimated to have a positive wave.
In May 2020, Philips has announced FDA approval for the product ‘Philips HeartStart FR3 Defibrillator and Accessories’. The HeartStart FR3 models 861388 and 861389 are used to treat ventricular fibrillation which are said to be abnormal heart rhythms, the most common cause of cardiac arrest. In addition to this in 2019, Stryker Corporation which is one of the leading market player in cardiac implants has launched the product LIFEPAK CR2 defibrillator with LIFELINKcentral AED program manager, in the United States. Considering the above conditions the market is expected to pave a positive direction.
Cardiac Implants Market Envisioned to Generate a CAGR of 7.2% from 2022-2031
Diagnostics Enzyme Market is Set to Experience a Significant Growth of 6.2% CAGR from 2022 To 2031
DNA/RNA Extraction Kit Market Size in 2022 : 7.26% CAGR with Top Countries Data, Key Regions and Growth Forecast to 2031
Non-Invasive Aesthetic Treatment Market is Poised to Grow at a CAGR of 12% during the Forecast Period of 2022-2031
Blood Platelets Market Size Predicted to Increase at a Positive CAGR Of 3% from 2022 to 2031
Enteral Feeding Tubes Market Envisioned to Generate a CAGR of 6% from 2022-2031
Medical Tricorder Device Market is Set to Experience a Significant Growth of 6.34% CAGR from 2022 To 2031